Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Mercury BiopharmaceuticalROCO:6932 -2.63%25 PB Ratio is 11.25 as of Jul. 15, 2026, which is 34% below its 10-year median of 16.97. GuruFocus rates ROCO:6932 with a GF Score™ of 25/100 and a GF Value™ of NT$36.00 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 921 Drug Manufacturers companies, Mercury Biopharmaceutical ranks worse than 93.49% on this metric.
The historical rank and industry rank for Mercury Biopharmaceutical's PB Ratio or its related term are showing as below:
ROCO:6932'
s PB Ratio Range Over the Past 10 Years
Min: 7.61 Med: 16.97 Max: 60.55
Current: 11.26
During the past 7 years, Mercury Biopharmaceutical's highest PB Ratio was 60.55. The lowest was 7.61. And the median was 16.97.
ROCO:6932's PB Ratio is ranked worse than 93.49% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.9
vs ROCO:6932: 11.26
During the past 12 months, Mercury Biopharmaceutical's average Book Value Per Share Growth Rate was -24.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 5.90% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Mercury Biopharmaceutical was 199.70% per year. The lowest was 5.90% per year. And the median was 102.80% per year.
Back to Basics: PB Ratio
Mercury Biopharmaceutical (ROCO:6932) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Mercury Biopharmaceutical PB Ratio Related Terms
Mercury Biopharmaceutical PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Mercury Biopharmaceutical's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mercury Biopharmaceutical PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mercury Biopharmaceutical's PB Ratio distribution charts can be found below:
* The bar in red indicates where Mercury Biopharmaceutical's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Mercury Biopharmaceutical (ROCO:6932) has a PB Ratio of 11.25 as of Jul. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Mercury Biopharmaceutical and its competitors. This is 34% below median its historical median of 16.97. Over the past decade, Mercury Biopharmaceutical's PB Ratio has ranged from 7.61 to 60.55. According to the industry distribution chart, Mercury Biopharmaceutical ranks #861 out of 921 companies in the Drug Manufacturers industry, placing it in the top 93.5%.
Is Mercury Biopharmaceutical's PB Ratio too high?
Mercury Biopharmaceutical's current PB Ratio of 11.25 is 34% below median its 10-year median of 16.97. Over the past 10 years, this metric has ranged from a low of 7.61 to a high of 60.55. The Drug Manufacturers industry median PB Ratio is 1.90. Mercury Biopharmaceutical's value of 11.25 is 492.1% above this industry median. Based on the distribution chart, Mercury Biopharmaceutical ranks #861 out of 921 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Mercury Biopharmaceutical has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mercury Biopharmaceutical's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Mercury Biopharmaceutical ranks #861 out of 921 companies for PB Ratio. This places Mercury Biopharmaceutical in the lower half of its industry. The industry median PB Ratio is 1.90. Mercury Biopharmaceutical's value of 11.25 is 492.1% above this benchmark. Historically, Mercury Biopharmaceutical's own PB Ratio has ranged from 7.61 to 60.55 over the past decade. While the company's 10-year median is 16.97 vs. the industry median of 1.90, Mercury Biopharmaceutical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.90, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mercury Biopharmaceutical's current PB Ratio of 11.25 is 492.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Mercury Biopharmaceutical and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mercury Biopharmaceutical's current PB Ratio is 11.25, which is 34% below median its own 10-year median of 16.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mercury Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Mercury Biopharmaceutical (ROCO:6932) is currently considered Possible Value Trap. The stock's GF Value™ is NT$36.00, compared to a current price of NT$5.93 — trading 83.5% below its estimated fair value. The current PB Ratio is 11.25, which is 34% below median its 10-year median of 16.97 and 492.1% above the Drug Manufacturers industry median of 1.90. Mercury Biopharmaceutical's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Mercury Biopharmaceutical (ROCO:6932), the current PB Ratio is 11.25 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mercury Biopharmaceutical (ROCO:6932) Overvalued in 2026?
Based on GuruFocus' analysis, Mercury Biopharmaceutical stock appears to be undervalued.
The current stock price of NT$5.93 is trading 83.5% below its estimated GF Value™ of NT$36.00.
GuruFocus considers Mercury Biopharmaceutical to be Possible Value Trap.
Key valuation signals for ROCO:6932:
PB Ratio: 11.25 (34% below median its 10-year median of 16.97)
GF Value™: NT$36.00 vs. price of NT$5.93 (83.5% below fair value)
Industry Position: 492.1% above the Drug Manufacturers median (#861 of 921)
No single metric tells the full story. See the ROCO:6932 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mercury Biopharmaceutical Corp focuses on the development of drugs for unmet medical needs. It offers a development platform focusing on rapid release and free adjustable doses. Its 3D powder bonding method (binder jetting) combines powder and special molding adhesive and stacks them in layers.
25GF Score
Get the complete analysis for ROCO:6932
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6932 has been successfully added to your 
